Entellus Medical Inc (ENTL) Insider Robert S. White Sells 3,471 Shares

Entellus Medical Inc (NASDAQ:ENTL) insider Robert S. White sold 3,471 shares of the firm’s stock in a transaction dated Friday, January 5th. The shares were sold at an average price of $24.01, for a total transaction of $83,338.71. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

Entellus Medical Inc (NASDAQ ENTL) traded down $0.06 during mid-day trading on Tuesday, reaching $24.07. 216,202 shares of the company’s stock were exchanged, compared to its average volume of 236,460. The company has a quick ratio of 1.71, a current ratio of 1.92 and a debt-to-equity ratio of 0.32. Entellus Medical Inc has a 52 week low of $11.47 and a 52 week high of $25.58. The stock has a market capitalization of $613.16 and a price-to-earnings ratio of -18.80.

Entellus Medical (NASDAQ:ENTL) last posted its quarterly earnings data on Wednesday, November 1st. The medical technology company reported ($0.49) EPS for the quarter, beating analysts’ consensus estimates of ($0.51) by $0.02. Entellus Medical had a negative net margin of 31.24% and a negative return on equity of 47.37%. analysts forecast that Entellus Medical Inc will post -1.33 EPS for the current year.

Several equities analysts have recently weighed in on the stock. Zacks Investment Research lowered shares of Entellus Medical from a “hold” rating to a “sell” rating in a research report on Wednesday, January 3rd. Canaccord Genuity restated a “hold” rating and set a $17.00 price objective on shares of Entellus Medical in a research report on Tuesday, October 17th. TheStreet upgraded shares of Entellus Medical from a “d” rating to a “c-” rating in a research report on Thursday, December 14th. ValuEngine upgraded shares of Entellus Medical from a “sell” rating to a “hold” rating in a research report on Thursday, December 7th. Finally, William Blair lowered shares of Entellus Medical from an “outperform” rating to a “market perform” rating in a research report on Friday, December 8th. Two investment analysts have rated the stock with a sell rating, four have given a hold rating and two have given a buy rating to the company. The stock has an average rating of “Hold” and an average target price of $19.25.

A number of hedge funds have recently bought and sold shares of the business. Neuberger Berman Group LLC lifted its stake in Entellus Medical by 152.2% during the third quarter. Neuberger Berman Group LLC now owns 58,000 shares of the medical technology company’s stock valued at $1,071,000 after buying an additional 35,000 shares in the last quarter. Wells Fargo & Company MN lifted its position in shares of Entellus Medical by 74.7% in the third quarter. Wells Fargo & Company MN now owns 11,329 shares of the medical technology company’s stock worth $209,000 after purchasing an additional 4,846 shares in the last quarter. Citadel Advisors LLC purchased a new stake in shares of Entellus Medical in the third quarter worth approximately $302,000. Archon Capital Management LLC lifted its position in shares of Entellus Medical by 14.9% in the third quarter. Archon Capital Management LLC now owns 550,224 shares of the medical technology company’s stock worth $10,157,000 after purchasing an additional 71,404 shares in the last quarter. Finally, JPMorgan Chase & Co. lifted its position in shares of Entellus Medical by 145.1% in the third quarter. JPMorgan Chase & Co. now owns 9,469 shares of the medical technology company’s stock worth $168,000 after purchasing an additional 5,605 shares in the last quarter. 78.24% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY WARNING: This piece of content was originally published by BBNS and is owned by of BBNS. If you are viewing this piece of content on another publication, it was copied illegally and reposted in violation of US and international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://baseballnewssource.com/markets/robert-s-white-sells-3471-shares-of-entellus-medical-inc-entl-stock/1821340.html.

Entellus Medical Company Profile

Entellus Medical, Inc is a medical technology company. The Company is focused on delivering patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis in both adult and pediatric patients. Its three core product lines, XprESS Multi-Sinus Dilation Systems, MiniFESS Surgical Instruments, and FocESS Imaging & Navigation, are designed to enable ear, nose and throat (ENT), physicians to perform a range of procedures in the ENT physician office and to simplify operating room-based treatment.

Insider Buying and Selling by Quarter for Entellus Medical (NASDAQ:ENTL)

Receive News & Ratings for Entellus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entellus Medical and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Rumor: Milwaukee Brewers Offer Yu Darvish Contract
Rumor: Milwaukee Brewers Offer Yu Darvish Contract
Report: 20-Second Clock and Limit on Mound Visits Rejected by MLBPA
Report: 20-Second Clock and Limit on Mound Visits Rejected by MLBPA
Christian Yelich’s Agent Says Relationship with Marlins is Broken
Christian Yelich’s Agent Says Relationship with Marlins is Broken
Houston Astros Add Starter to Rotation
Houston Astros Add Starter to Rotation
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Justin Morneau Former Star With Twins and AL MVP Retires
Justin Morneau Former Star With Twins and AL MVP Retires


Leave a Reply

 
© 2006-2018 BBNS.